184 related articles for article (PubMed ID: 35579925)
1. Patents And Regulatory Exclusivities On Inhalers For Asthma And COPD, 1986-2020.
Feldman WB; Bloomfield D; Beall RF; Kesselheim AS
Health Aff (Millwood); 2022 Jun; 41(6):787-796. PubMed ID: 35579925
[TBL] [Abstract][Full Text] [Related]
2. Patenting Strategies on Inhaler Delivery Devices.
Demkowicz BJ; Tu SS; Kesselheim AS; Carrier MA; Feldman WB
Chest; 2023 Aug; 164(2):450-460. PubMed ID: 36842533
[TBL] [Abstract][Full Text] [Related]
3. Patent Challenges And Litigation On Inhalers For Asthma And COPD.
Reddy S; Beall RF; Tu SS; Kesselheim AS; Feldman WB
Health Aff (Millwood); 2023 Mar; 42(3):398-406. PubMed ID: 36877911
[TBL] [Abstract][Full Text] [Related]
4. Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986-2019.
Olsen A; Beall RF; Knox RP; Tu SS; Kesselheim AS; Feldman WB
PLoS Med; 2023 Nov; 20(11):e1004309. PubMed ID: 37971985
[TBL] [Abstract][Full Text] [Related]
5. Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists.
Alhiary R; Kesselheim AS; Gabriele S; Beall RF; Tu SS; Feldman WB
JAMA; 2023 Aug; 330(7):650-657. PubMed ID: 37505513
[TBL] [Abstract][Full Text] [Related]
6. Switching from branded to generic inhaled medications: potential impact on asthma and COPD.
Lavorini F; Ninane V; Haughney J; Bjermer L; Molimard M; Dekhuijzen RP
Expert Opin Drug Deliv; 2013 Dec; 10(12):1597-602. PubMed ID: 24224777
[TBL] [Abstract][Full Text] [Related]
7. Cost saving of switching to equivalent inhalers and its effect on health outcomes.
Bloom CI; Douglas I; Olney J; D'Ancona G; Smeeth L; Quint JK
Thorax; 2019 Nov; 74(11):1078-1086. PubMed ID: 31383774
[TBL] [Abstract][Full Text] [Related]
8. Determinants of Market Exclusivity for Prescription Drugs in the United States.
Kesselheim AS; Sinha MS; Avorn J
JAMA Intern Med; 2017 Nov; 177(11):1658-1664. PubMed ID: 28892528
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.
Brocklebank D; Ram F; Wright J; Barry P; Cates C; Davies L; Douglas G; Muers M; Smith D; White J
Health Technol Assess; 2001; 5(26):1-149. PubMed ID: 11701099
[TBL] [Abstract][Full Text] [Related]
10. Is Patent "Evergreening" Restricting Access to Medicine/Device Combination Products?
Beall RF; Nickerson JW; Kaplan WA; Attaran A
PLoS One; 2016; 11(2):e0148939. PubMed ID: 26910128
[TBL] [Abstract][Full Text] [Related]
11. The timing of 30-month stay expirations and generic entry: A cohort study of first generics, 2013-2020.
Kannappan S; Darrow JJ; Kesselheim AS; Beall RF
Clin Transl Sci; 2021 Sep; 14(5):1917-1923. PubMed ID: 33982425
[TBL] [Abstract][Full Text] [Related]
12. Characteristics Of Key Patents Covering Recent FDA-Approved Drugs.
Van de Wiele VL; Torrance AW; Kesselheim AS
Health Aff (Millwood); 2022 Aug; 41(8):1117-1124. PubMed ID: 35914209
[TBL] [Abstract][Full Text] [Related]
13. Maintenance inhaler preference, attribute importance, and satisfaction in prescribing physicians and patients with asthma, COPD, or asthma-COPD overlap syndrome consulting for routine care.
Ding B; Small M; Scheffel G; Holmgren U
Int J Chron Obstruct Pulmon Dis; 2018; 13():927-936. PubMed ID: 29588581
[TBL] [Abstract][Full Text] [Related]
14. Asthma and COPD: Interchangeable use of inhalers. A document of Italian Society of Allergy, Asthma and Clinical Immmunology (SIAAIC) & Italian Society of Respiratory Medicine (SIMeR).
Lavorini F; Braido F; Baiardini I; Blasi F; Canonica GW;
Pulm Pharmacol Ther; 2015 Oct; 34():25-30. PubMed ID: 26209820
[TBL] [Abstract][Full Text] [Related]
15. Device errors in asthma and COPD: systematic literature review and meta-analysis.
Chrystyn H; van der Palen J; Sharma R; Barnes N; Delafont B; Mahajan A; Thomas M
NPJ Prim Care Respir Med; 2017 Apr; 27(1):22. PubMed ID: 28373682
[TBL] [Abstract][Full Text] [Related]
16. Asthma and chronic obstructive pulmonary disease inhalers: Techniques for proper use.
Pepper AN; Cooke A; Livingston L; Lockey RF
Allergy Asthma Proc; 2016 Jul; 37(4):279-90. PubMed ID: 27401315
[TBL] [Abstract][Full Text] [Related]
17. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals.
Hao J; Rodriguez-Monguio R; Seoane-Vazquez E
PLoS One; 2015; 10(10):e0140708. PubMed ID: 26469277
[TBL] [Abstract][Full Text] [Related]
18. Optimizing drug delivery in COPD: The role of inhaler devices.
Rogliani P; Calzetta L; Coppola A; Cavalli F; Ora J; Puxeddu E; Matera MG; Cazzola M
Respir Med; 2017 Mar; 124():6-14. PubMed ID: 28284323
[TBL] [Abstract][Full Text] [Related]
19. Misuse and/or treatment delivery failure of inhalers among patients with asthma or COPD: A review and recommendations for the conduct of future research.
Mahon J; Fitzgerald A; Glanville J; Dekhuijzen R; Glatte J; Glanemann S; Torvinen S
Respir Med; 2017 Aug; 129():98-116. PubMed ID: 28732842
[TBL] [Abstract][Full Text] [Related]
20. A Method for Approximating Future Entry of Generic Drugs.
Beall RF; Darrow JJ; Kesselheim AS
Value Health; 2018 Dec; 21(12):1382-1389. PubMed ID: 30502781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
